Articles tagged with Drug Discovery
A new drug targeting brain inflammation, MW-151, is ready for its first round of human testing. The medication aims to block 'bad' inflammation that destroys neurons in Alzheimer's disease.
Researchers have discovered parameters governing drug encapsulation, giving more control over the slow release of drugs in patients. This breakthrough enables fewer trial-and-error experiments in drug design, reducing side effects and facilitating personalized therapeutic treatments.
Researchers from Peking University and Insilico Medicine are collaborating on AI-powered drug discovery methods, aiming to accelerate pharmaceutical research and development. The project will focus on various applications of AI in drug discovery, including target identification, compound generation, and personalized medicine.
Virginia Tech professor Webster Santos has received a grant to discover drugs that inhibit a small molecule transporter, which modulates the immune system and could treat multiple sclerosis. The collaboration aims to develop SPNS2 inhibitors for treating MS and metastatic cancers.
Researchers developed 13 bioluminescence sensors to measure intracellular signaling pathways and detect pharmaceutical action. The biosensors provide a complete answer, or 'signaling profile,' allowing for more accurate drug testing and development.
Researchers have developed a strategy to create new small-molecule drugs by reprogramming rapamycin. A library of 45,000 altered molecules was screened to identify a new compound, rapadocin, that inhibits cellular nucleoside uptake without toxicity. Rapadocin targets ENT1 protein and shows promise for treating kidney injury.
Researchers at EPFL developed a photoelectrocatalytic arene C-H amination method, producing pharmaceutical molecules like metaxalone and benzethonium chloride. Hematite semiconductor is used as a catalyst under visible light, offering a low-cost and energy-efficient alternative to traditional methods.
The open-science model is being expanded to neurodegenerative diseases such as Parkinson's and Amyotrophic Lateral Sclerosis. M4ND Pharma will pursue promising new genetic drug targets, sharing progress with the scientific community through regular online meetings.
A machine learning algorithm has been developed to speed up the process of discovering new medicines, identifying four new molecules that activate a protein relevant to symptoms of Alzheimer's disease and schizophrenia. The algorithm is twice as efficient as industry standards and can analyze vast amounts of chemical data.
Scientists at UCSF have developed the world's largest virtual pharmacology platform, enabling them to screen hundreds of millions of never-before-synthesized compounds for potential drugs. The platform has identified remarkably potent antibacterial and psychiatric drug candidates.
Scientists have created an 'unclonable' tag that can never be replicated, using physical unclonable functions (PUFs) with microparticles forming random patterns. The system correctly identified 76% of the tags, with estimated 2.5 x 10^120 unique codes.
Researchers identified a new process capable of generating antibiotic resistance in bacteria up to 600 million years ago. The discovery highlights the need for combined multidrug treatments and reduced agricultural use of antibacterials.
A University of Illinois team has created a synthetic manganese catalyst that can oxidize aliphatic scaffolds in the presence of aromatics, enabling chemists to produce new drugs from old ones. The discovery could expedite the drug discovery process and identify metabolites without requiring new syntheses.
USC scientists have made groundbreaking discoveries about a tick-borne virus, including its molecular mechanisms and potential therapeutic targets. The research could lead to the development of medications and a vaccine to prevent or treat hemorrhagic fever.
Researchers at Purdue University have discovered two peptides that selectively activate beneficial cellular pathways without causing unwanted side effects. These peptides are being investigated in preclinical studies for their ability to regulate dietary intake and have shown promising results.
Kinetoplastid and apicomplexan parasites are targeted by inhibiting thymidylate biosynthesis, leading to decreased dTTP levels and cell death. Novel inhibitors with anti-parasitic activity have been identified in the review.
The article discusses how reperfusion injury amplifies cell damage after tissue perfusion. Calcium handling mechanisms, including Ca2+ ion elevation, predispose patients to mitochondrial failure, hyper-contracture, and proteolysis.
A study by the University of São Paulo's Biomedical Science Institute shows that sofosbuvir can eliminate both chikungunya and yellow fever viruses without damaging human cells. This finding has significant implications for public health, particularly in Brazil where a chikungunya epidemic is forecasted.
A new study assesses the reliability of CETSA HT for early drug discovery, demonstrating good correlations with other assay formats. The technology highlights different compound responses, providing a better understanding of cellular effects.
Researchers found that metformin and syrosingopine combination blocks critical energy production step, driving cancer cells to death. The duo targets NAD+ regeneration, preventing lactate export and leading to cell demise.
Researchers at Weizmann Institute of Science have revealed a previously unknown mechanism underlying anxiety. Targeting this biochemical pathway may help develop new therapies for alleviating the symptoms of anxiety disorders.
Ruiwen Zhang, a University of Houston College of Pharmacy scientist, has been recognized as a leader in cancer prevention and treatment drug discovery and development. He has made major contributions to the discovery of cancer pharmacogenetic/pharmacogenomic syndrome and developed novel gene silencing technologies.
A comprehensive review highlights novel approaches to slow or prevent Alzheimer's disease, focusing on the effects of aging on the brain. Combination therapy is deemed necessary for better treatment outcomes, similar to other major diseases.
A new research developed a platform to predict compounds with clinical potential for treating brain diseases. The platform uses machine learning and whole-brain activity imaging to identify drugs with higher therapeutic and clinical translation potential, accelerating the drug development process.
A recent paper by Insilico Medicine introduces deep learning for aging research, revealing age as a key biological feature that can be predicted using various data types. The study also outlines the potential applications of this technology, including personalized immunotherapies and vaccinations.
Researchers use cryo-electron microscopy to capture detailed snapshots of the TFIID molecule's dynamic structure as it interacts with DNA. The high-resolution images reveal new insights into the molecular mechanism and provide opportunities for developing drugs that target its structural changes.
Researchers at Colorado State University have created a new carbon-carbon bond reaction using phosphorus to stitch together molecular rings called pyridines. This reaction could fling open an underexplored wing of biologically relevant chemistry, allowing for the discovery of new drugs.
Researchers at UCI School of Medicine have discovered the molecular basis for therapeutic actions of an African folk medicine used to treat various illnesses, including diabetes and epilepsy. The study found two components of the Mallotus leaf extract bind to a previously unrecognized binding site on KCNQ1 potassium channels.
A multidisciplinary research team has provided fundamental new insight into the mechanism of dimethyl fumarate, a medical drug used to treat multiple sclerosis and psoriasis. The results describe an allosteric covalent inhibition of p90 ribosomal S6 kinases, pointing to an effective mechanism of kinase inhibition.
Researchers at Kanazawa University have identified three new compounds from the leaves of a threatened tropical plant species with potent antiproliferative activities against various human tumor cell lines. The study highlights the potential of rainforest plants as a rich source of bioactive natural products for cancer drug discovery.
Researchers at University of Montreal discovered how metformin affects cell glucose uptake and metabolism, revealing a link to iron distribution. This finding may explain metformin's potential benefits beyond diabetes treatment, including prevention of chronic diseases like cancer.
Purdue researchers, including Nobel Prize winner Ei-ichi Negishi, developed a new chemical process to synthesize drug-like molecules with ultra-high purity. The technology produces high yields and has a broad scope for use among boron-based drugs.
The special issue brings together contributions from top academics and industry experts, highlighting the use of generative chemistry and GANs for de-novo molecular design. Experimental validation of generated molecules demonstrates high activity and selectivity in a novel inhibitor of Janus Kinase 3.
Researchers found a new mechanism involving KCNB1 potassium channels that builds up toxins in brains affected by Alzheimer's disease. The build-up is caused by oxidation and can also contribute to other conditions such as traumatic brain injury.
Researchers at OHSU have discovered the three-dimensional structure of a membrane channel critical in controlling blood pressure. The breakthrough provides a starting point for developing better treatments for diseases associated with this channel, including severe hypertension and heart failure.
Researchers at GC/CUNY have made a major breakthrough in controlling the 3D structure of molecules, enabling the rapid modification of molecular structures used in drug discovery. This new process offers tremendous promise for developing novel drug molecules with medicinal or industrial applications.
The research collaboration aims to create human organs-on-chips using miniature devices that mimic specific tissues and organs. These organs-on-chips have the potential to predict drug activity and toxicity more accurately than animal models.
Researchers at Sanford Burnham Prebys Medical Discovery Institute have found that amodiaquine suppresses blood vessel formation through both the apelin and VEGF pathways, reversing vascular eye damage in animal models. The compound blocks the receptor's function by binding to a unique area, inhibiting apelin's ability to drive blood ve...
Researchers at Insilico Medicine developed an Entangled Conditional Adversarial Autoencoder (ECAAE) that generates molecular structures based on various properties. The generated molecule demonstrated high activity and selectivity against a specific protein, laying the foundation for AI-powered drug discovery.
Pharmaceutical companies are adopting improved safety screening strategies to enhance the drug discovery process, including integrated screening paradigms and computational methods. These approaches aim to identify higher-quality drug candidates and mitigate off-target toxicity.
Researchers at UTSA made a groundbreaking discovery involving the regulation of thiols in mammals. The study found that human bodies may be capable of breaking fluorine-carbon bonds in drugs, opening new possibilities for pharmaceutical treatments.
Researchers have crystallized serotonin receptors bound to several compounds, revealing why some drugs cause severe side effects while others do not. The study provides valuable insight into the receptor's structure and binding mechanisms, enabling drug developers to create safer and more effective medications.
Researchers at the University of Zurich have developed a new method for alleviating chronic itch by targeting specific neurons in the spine that prevent itch signals from being relayed to the brain. The experimental drug has been shown to be effective in mice and dogs, with significant reductions in scratching and improved skin healing.
The Harrington Discovery Institute has announced three new scholars in collaboration with FFB and ADDF, selected through a competitive review process for their research on therapies for retinal degenerative diseases and Alzheimer's disease. The institute provides financial support and drug development assistance to accelerate these pro...
Scripps Research scientists have developed a powerful new strategy for synthesizing molecular skeletons of chemicals used in drugs and other important products. The method combines two chemical reactions, C-C cross coupling and cycloaddition, providing unprecedented flexibility and control over chemical synthesis.
A new compound with potential to treat visceral leishmaniasis has been discovered through collaboration between the University of Dundee, GSK and Wellcome. The compound works by inhibiting an enzyme called CRK12, offering a novel approach to tackling the disease.
This special issue showcases recent advances in high-throughput flow cytometry for drug discovery, including novel applications and expert insights. Examples include HTFC for single-cell analysis, biologic drugs, and CAR-T therapy.
Researchers at the University of Pennsylvania and Syracuse University have developed a compound that effectively controls hyperglycemia in animal trials without causing nausea and vomiting. The modified compound is less absorbed into brain regions that trigger these side effects, leading to vastly improved tolerance.
Researchers at Cardiff University have developed a potential new treatment for schistosomiasis and fascioliasis, two devastating tropical diseases. The goji berry-derived drug compound shows promise in combating the parasites that cause these conditions.
Scientists have identified two small-molecule compounds that specifically target the STING protein, which plays a key role in triggering an immune response. These compounds effectively blocked STING-mediated cellular activation and demonstrated therapeutic potential in mouse models of autoinflammatory disease.
Researchers at University of Otago have discovered a novel property of Bedaquiline, a new anti-tuberculosis drug that could help develop more effective treatments for tuberculosis. The study's findings suggest that the drug works by disrupting energy generation in Mycobacterium tuberculosis cells, offering potential for designing more ...
Insilico Medicine introduces a novel deep neural network architecture called Reinforced Adversarial Neural Computer (RANC) for de novo molecular design. RANC outperforms other methods in generating unique structures and passing medical chemistry filters.
A new study by Scripps Research reveals that bacteria-derived molecules called thiocarboxylic acids have potential as warheads and could be used to create more effective drugs. The discovery was made after researchers found that these natural products can bind to biological targets better than lab-made molecules.
AcuraStem has been awarded a $3.7 million SBIR grant to continue research on a small molecule therapeutic for ALS, utilizing induced motor neuron cellular models and precision platform iNeuroRx°. The grant supports the development of AS2015, targeting expansion repeats in the C9ORF72 gene.
A recent international agreement emphasizes the need for human-relevant research in drug discovery, citing a significant decline in successful new drug approvals. The agreement proposes standardized data sharing, consistent ontologies, and prioritization of human-based methods to revitalize the drug development process.
Researchers discovered a chemical compound that lowers sugar levels as effectively as metformin but with a 30-times lower dose, providing an alternative treatment option for patients unresponsive to the current medication. The study published in PLOS One could lead to the development of a new and effective drug to fight diabetes.
Researchers at UBC's Okanagan campus found that men who have used psychedelic drugs are less likely to engage in partner violence. The study suggests that psychedelics may help improve emotion regulation and reduce violent tendencies.
Clinical Trials in a Dish (CTiD) offers a novel strategy to test drugs on patient cells before moving into actual clinical trials. CTiD studies have opened up new avenues for screening cell-based safety and toxicity at the population level, enabling efficient testing with reduced costs.
Researchers have found a link between bacteria metabolism and cell-to-cell communication, which could lead to the development of new drugs that block toxic molecules or prevent biofilm formation. By disrupting quorum sensing and biofilm forming in bacteria, these drugs may prevent infections such as urinary tract infections.
The study reveals unexpected molecular behavior in ultra-nanoscale channels, where neutral molecules behave as though carrying a charge. The team developed an algorithm for selecting optimal nanochannel size for each drug, but found that current theories were unable to explain the observed effects.